American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy.
about
KRAS mutational analysis for colorectal cancer. Application: pharmacogenomicMulti-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancerActivation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximabPredictive Biomarkers in Colorectal Cancer: From the Single Therapeutic Target to a Plethora of OptionsCurrent targeted therapies in the treatment of advanced colorectal cancer: a reviewPharmacologic resistance in colorectal cancer: a reviewMolecular approach to genetic and epigenetic pathogenesis of early-onset colorectal cancerSomatic DNA mutation analysis in targeted therapy of solid tumoursAssessing value of innovative molecular diagnostic tests in the concept of predictive, preventive, and personalized medicinePrecision medicine in colorectal cancer: the molecular profile alters treatment strategiesPersonalized treatment for advanced colorectal cancer: KRAS and beyondK-Ras Mutations in Non-Small-Cell Lung Cancer: Prognostic and Predictive ValueRecent applications of chemosensitivity tests for colorectal cancer treatmentSpecificity delivers: therapeutic role of tumor antigen-specific antibodies in pancreatic cancerMolecular alterations and biomarkers in colorectal cancerCancer biomarkersColorectal Cancer Biomarkers: Where Are We Now?Novel immunotherapeutic strategies of gastric cancer treatmentGuanylyl cyclase C as a biomarker in colorectal cancerPrimary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategiesGenetic and epigenetic traits as biomarkers in colorectal cancerIdentification of clinically relevant molecular subtypes in colorectal cancer: the dawning of a new eraDasatinib sensitizes KRAS mutant colorectal tumors to cetuximabmTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors.Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials.The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.Recent Advances in Chemotherapy and Surgery for Colorectal Liver MetastasesMolecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future PerspectiveRAS isoforms and mutations in cancer at a glanceMechanisms of resistance to anti-EGFR therapy in colorectal cancerRAS and BRAF in metastatic colorectal cancer managementPanitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS StatusExtended RAS testing in metastatic colorectal cancer-Refining the predictive molecular biomarkersERK2-Dependent Phosphorylation of CSN6 Is Critical in Colorectal Cancer DevelopmentMutant allele-specific imbalance modulates prognostic impact of KRAS mutations in colorectal adenocarcinoma and is associated with worse overall survivalCetuximab response in CRC patient-derived xenografts seems predicted by an expression based RAS pathway signaturePCR-based assays versus direct sequencing for evaluating the effect of KRAS status on anti-EGFR treatment response in colorectal cancer patients: a systematic review and meta-analysisPhase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancerAllele specific locked nucleic acid quantitative PCR (ASLNAqPCR): an accurate and cost-effective assay to diagnose and quantify KRAS and BRAF mutation
P2860
Q21128654-ED26ACE5-9487-4C04-AB69-24DAE3DA1524Q21142734-744D98C9-11FA-4C96-8695-1F3DAD35C37DQ24600031-5EB63E4D-6984-4B9F-8D42-45246EB57F17Q26738655-41FEACD5-EBA4-4E4B-99CC-55A272FF71B2Q26740067-483619F4-012B-4504-97F3-21F2EDBAF34FQ26769850-20496A6E-FA47-4F51-A727-1FCAC34D2B5DQ26769935-E3CCB3C8-6586-48D3-AFCB-AB2A5353B85DQ26770324-A7A239F0-971C-44BD-AF27-4AF7E05FA01EQ26783472-4CC536C3-B1BF-4262-A945-3D59E72708E2Q26795558-33AC538B-E0EC-4F4E-B3FB-BE5F805D9B32Q26822817-E3A29A90-0A13-43C7-85CD-1D8EC142D179Q26829425-BB3E2B04-6230-4274-BAD8-13F3B67318D2Q26851075-9F89B034-F96E-465C-9A9C-9C42288D3CFAQ26853171-A5F1EC28-5089-4C9D-82FD-E813F0C7747BQ26862317-73F6731F-BF33-4990-BA91-261C62A131FDQ26864429-37385485-3676-4666-95F9-227CC4010DF9Q27003134-3A286A6B-12E5-4B6D-B119-87C31F1E9FC1Q27011232-596F5770-E6C2-45ED-86F2-4B3934C32DE6Q27011759-B785C273-CF82-47F8-AFDB-9FC70FEA2371Q27015224-898C7A2E-1273-419F-AD18-130212CC462EQ27016019-4D008E22-AA8C-4B7A-8716-5567CD423D8EQ27693248-19AFE19E-09D6-48AF-8BAF-FCC7FB602036Q27851586-4ECA7D8B-B0FB-419A-A193-2C9272B74B60Q27851707-C0C9CCE5-A4C1-4BDA-B13F-71B4813A3D14Q27851892-CD0A913C-B93D-402C-92ED-D1403626798BQ27852988-50CC06CB-B95B-449D-86BF-924D99CBAAC2Q27853338-896FA2CB-31E1-4FB7-AEE0-820836C7A040Q28067408-DD433D5B-C53C-4537-B2D6-918E4C760DC2Q28070038-CEB8FE30-DABA-4E13-BAC7-C43626FFCC31Q28070394-93E23B8A-6B77-4FB4-B369-3D32A7BD3105Q28074073-1D7844C0-119F-4CB0-BFE3-D3C4D2CCA8ABQ28074175-E3E3C42C-2454-47DB-8A29-FBF2AF83E25EQ28082816-4E783BEC-D2AB-4077-84F2-C81395CB244CQ28087333-88F9CA09-CF5A-4981-ACBD-405D8A418E5AQ28115416-1F3CB590-7E40-40D5-97AB-E346A9AC7919Q28258483-0FE9B89B-E807-465C-A14F-3481389E3DCEQ28468648-3C589EA5-5A98-46A0-9ADC-1297301DF3C1Q28543278-4BE69C46-DFA2-4D90-B77A-3DA89C599C4EQ28728593-EBAD48AC-FCF1-4CF7-BBE2-CAFE9BE4DFE5Q28730199-A8F53C2D-ECC1-41D9-9480-28212FAE7A26
P2860
American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy.
description
2009 nî lūn-bûn
@nan
2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
American Society of Clinical O ...... r monoclonal antibody therapy.
@ast
American Society of Clinical O ...... r monoclonal antibody therapy.
@en
American Society of Clinical O ...... r monoclonal antibody therapy.
@nl
type
label
American Society of Clinical O ...... r monoclonal antibody therapy.
@ast
American Society of Clinical O ...... r monoclonal antibody therapy.
@en
American Society of Clinical O ...... r monoclonal antibody therapy.
@nl
prefLabel
American Society of Clinical O ...... r monoclonal antibody therapy.
@ast
American Society of Clinical O ...... r monoclonal antibody therapy.
@en
American Society of Clinical O ...... r monoclonal antibody therapy.
@nl
P2093
P356
P1476
American Society of Clinical O ...... r monoclonal antibody therapy.
@en
P2093
Carmen J Allegra
Daniel F Hayes
Elizabeth H Hammond
J Milburn Jessup
Mark R Somerfield
Pamela K McAllister
Richard L Schilsky
Roscoe F Morton
Stanley R Hamilton
P304
P356
10.1200/JCO.2009.21.9170
P407
P577
2009-02-02T00:00:00Z